EGFR and non-small cell lung carcinoma: For example, in NSCLC patients harboring EGFR gene mutations, the EGFR-TKI class of drugs is the standard first-line treatment, showing disease progression after 9–13 months despite some therapeutic efficacy (Kelly et al., 2015).